Transgene

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40
Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 551
Lid geworden op: 06 Sep 2018 20:48
waarderingen: 204
Contact:

Re: Transgene

Berichtdoor Naz-T » 02 Mei 2019 20:10

Jelle R schreef:Is dit dan de uitbraak waar we al zo lang op wachten? Technisch gezien is dit een zeer belangrijke uitbraak.

Oei, ik ben vandaag met lichte winst uitgestapt. Morgen dan best terug op de trein springen zeker? :oops:



Word gratis lid op Beursig.com

Discussieer met duizenden beleggers en profiteer
van minder advertenties en abonneer op onderwerpen.

Registreer nu binnen enkele tellen



powered by Surfing Waves

Gebruikersavatar
And its gone!
Forum gebruiker
Forum gebruiker
Berichten: 175
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 74
Contact:

Re: Transgene

Berichtdoor And its gone! » 13 Mei 2019 21:21

BRIEF-Transgene Cash Position At End-Q1 9.1 Million Euros
17:51 (13/05) - Bron: Reuters
May 13 (Reuters) - TRANSGENE SA TRNG.PA :
* EUR 9.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH
31,
2019
* KEY CLINICAL TRIALS CONFIRMED TO READOUT IN H2 2019
* €20 MILLION REVOLVING CREDIT FACILITY SECURED WITH NATIXIS
* TRANSGENE EXPECTS ITS CASH BURN FOR 2019 TO BE BETWEEN EUR
15
MILLION AND EUR 20 MILLION
* Q1 OPERATING REVENUE EUR 1.9 MILLION VERSUS EUR 1.8
MILLION YEAR
AGO
* HAS EXTENDED ITS FINANCIAL VISIBILITY TO Q4 2020
* CONFIRMS THAT IT EXPECTS READOUTS FROM ITS KEY CLINICAL
TRIALS
IN SECOND HALF OF 2019

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))


Financial visibility extended to Q4 2020, including $10 million revenue from
collaboration with AstraZeneca to be received in Q2 2019
✓ €9.1 Million in Cash and Cash Equivalents as of March 31, 2019
✓ €20 million revolving credit facility secured with Natixis
✓ Key clinical trials confirmed to readout in H2 2019
Strasbourg, France, May 13, 2019, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that
designs and develops virus-based immunotherapies against cancers and infectious diseases to transform the
fight against solid tumors and infectious diseases, today announces its business update for the quarter ending
March 31, 2019.
Operating revenue:
The following table summarizes the first quarter operating revenue for 2019 compared to the same period in
2018:
Q1
In millions of euros 2019 2018
Revenue from collaborative and licensing agreements 0.4 0.2
Government financing for research expenditures 1.5 1.6
Operating revenue 1.9 1.8
During the first quarter of 2019, revenue from collaborative and licensing agreements was mainly composed of
research services and royalties.
As of March 31, 2019, government financing for research expenditures mainly consisted of 25% of the research
tax credit expected for 2019 (€1.5 million in the first quarter of 2019, compared to €1.6 million for the same
period in 2018).
Cash, cash equivalents, available-for-sale financial assets and other financial assets:
In the first quarter of 2019, Transgene’s cash burn was €7.8 million, compared to €5.8 million for the same period
in 2018. Cash, cash equivalents, available-for-sale financial assets and other financial assets stood at €9.1 million
as of March 31, 2019, compared to €16.9 million as of December 31, 2018. This cash position does not include
the €20 million credit facility available for the Company or the $10 million receivable from AstraZeneca.
Key achievements:
• Finance:
o Transgene secured a €20 million revolving credit facility with a 30-month term with Natixis.
Transgene will be able to draw on and repay the facility at its discretion. Transgene has used its
shares in the Chinese biotech company Tasly Biopharmaceuticals as collateral for this loan (press
Page 2 / 3
release distributed on March 18, 2019). As of May 13, 2019, the Company has not drawn down
on this facility.
• Invir.IO™:
o Transgene and AstraZeneca signed a collaborative research, option and exclusive license
agreement to co-develop five armed oncolytic vaccinia virus candidates deriving from the
Invir.IO™ platform.
Transgene is to receive $10 million in Q2 2019 and additional pre-clinical success milestones of
up to $3 million. Transgene is eligible to receive an option exercise payment on each candidate
in the event AstraZeneca exercises one or more of its license option, as well as development and
commercial milestones and royalties (press release distributed on May 2, 2019).
o Transgene and BioInvent extend their collaboration to develop additional multifunctional
oncolytic viruses encoding for antibodies capable of treating a broad range of solid tumors (press
release distributed on March 26, 2019).
• myvac™:
o Transgene announced that the NEOVIVA project, that is focused on Transgene’s individualized
immunotherapy platform myvac™, was selected by the “Investments for the Future” Program
(Programme d’Investissements d’Avenir) operated by Bpifrance. The NEOVIVA project will
receive €5.2 million over the five-year duration of the program from Bpifrance, of which
Transgene will receive €2.6 million (press release distributed on March 13, 2019).
• TG4050:
o Transgene announced its decision to initiate clinical developments of its lead myvac™
candidate, TG4050, and the finalization of its collaboration agreement with NEC (press release
distributed on March 5, 2019).
o Transgene received FDA IND clearance for TG4050 to commence clinical development in ovarian
cancer (press release distributed on May 13, 2019).
Outlook:
Transgene expects its cash burn for 2019 to be between €15 million and €20 million, based on its current
development plan and cash-in from the collaboration with AstraZeneca.
As a result of the financing agreement with Natixis and the signing of the collaboration with AstraZeneca,
Transgene has extended its financial visibility to Q4 2020.
Transgene confirms that it expects readouts from its key clinical trials in the second half of 2019.
- End -
Laatst gewijzigd door And its gone! op 13 Mei 2019 21:51, 1 keer totaal gewijzigd.
Gillepils liked last!
GOOGL DBK BAYN TNG IVA IPH ASIT XON GERN

Gebruikersavatar
And its gone!
Forum gebruiker
Forum gebruiker
Berichten: 175
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 74
Contact:

Re: Transgene

Berichtdoor And its gone! » 13 Mei 2019 21:24

BRIEF-Transgene Receives FDA Clearance To Commence Clinical Development In Ovarian Cancer For TG4050
07:39 (13/05) - Bron: Reuters
May 13 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™
INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL
DEVELOPMENT IN OVARIAN CANCER
* TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™
INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL
DEVELOPMENT IN OVARIAN CANCER
* RECEIVED INVESTIGATIONAL NEW DRUG (IND) CLEARANCE FROM FDA
TO
PROCEED WITH A PHASE 1 CLINICAL TRIAL OF ITS LEAD MYVAC™
CANDIDATE TG4050
* PHASE 1 CLINICAL TRIAL WILL EVALUATE SAFETY AND
TOLERABILITY OF
TG4050 IN PATIENTS WITH OVARIAN, FALLOPIAN OR PERITONEAL SEROUS
CELL CARCINOMA
* STUDY, SPONSORED BY TRANSGENE, WILL BE CO-FINANCED BY
TRANSGENE
AND ITS PARTNER NEC
* PHASE 1 CLINICAL TRIAL, EXPECTED TO START IN H2 2019

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
GOOGL DBK BAYN TNG IVA IPH ASIT XON GERN

Jelle R
Forum gebruiker
Forum gebruiker
Berichten: 162
Lid geworden op: 13 Sep 2018 11:31
waarderingen: 41
Contact:

Re: Transgene

Berichtdoor Jelle R » 14 Mei 2019 18:00

Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...

Gebruikersavatar
And its gone!
Forum gebruiker
Forum gebruiker
Berichten: 175
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 74
Contact:

Re: Transgene

Berichtdoor And its gone! » 16 Mei 2019 17:55

Jelle R schreef:Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...


Ondertussen zitten we weer in de oude vertrouwde regio 2.8-3€ :lol:
GOOGL DBK BAYN TNG IVA IPH ASIT XON GERN

Jelle R
Forum gebruiker
Forum gebruiker
Berichten: 162
Lid geworden op: 13 Sep 2018 11:31
waarderingen: 41
Contact:

Re: Transgene

Berichtdoor Jelle R » 16 Mei 2019 20:40

And its gone! schreef:
Jelle R schreef:Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...


Ondertussen zitten we weer in de oude vertrouwde regio 2.8-3€ :lol:


Ongelooflijk he? :roll: Dacht met het nieuws van AstraZeneca en de uitbraak dat we eindelijk een uptrend te pakken zouden hebben, maar weer wordt alles direct teruggedraaid. Er zijn toch geen partijen die baat hebben om de koers niet ver boven de 3€ te laten stijgen? Al sinds het najaar van 2015 dobberen we rond de 3€...

Stefkamielkafkajr
Forum actieveling
Forum actieveling
Berichten: 505
Lid geworden op: 25 Dec 2013 21:48
waarderingen: 114
Contact:

Re: Transgene

Berichtdoor Stefkamielkafkajr » 17 Mei 2019 15:03

Jelle R schreef:
And its gone! schreef:
Jelle R schreef:Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...


Ondertussen zitten we weer in de oude vertrouwde regio 2.8-3€ :lol:


Ongelooflijk he? :roll: Dacht met het nieuws van AstraZeneca en de uitbraak dat we eindelijk een uptrend te pakken zouden hebben, maar weer wordt alles direct teruggedraaid. Er zijn toch geen partijen die baat hebben om de koers niet ver boven de 3€ te laten stijgen? Al sinds het najaar van 2015 dobberen we rond de 3€...

ik vrees eerder dat er een uitbraak richting beneden zal komen
begin hier serieus mijn geduld te verliezen
Agfa, , Deceuninck , euronav, exmar , acacia pharma,fagron,altice europe, nyrstar,transgene, aurora cannabis ,mdxhealt, pharming, , econocom